• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is First EU REDEMPLO Approval in FCS Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?

    Simply Wall St·08/18/2026 10:34:30
    Listen to the news
    • Arrowhead Pharmaceuticals has already obtained European marketing authorisation for REDEMPLO (plozasiran) to help reduce triglyceride levels in adults with familial chylomicronaemia syndrome, based on positive Phase 3 PALISADE data showing significant median fasting triglyceride reductions versus placebo at the 25 mg dose.
    • This approval marks Arrowhead’s transition from a pure development-stage RNAi player toward commercialisation in a rare disease with high unmet medical need and serious pancreatitis risk.
    • We’ll now examine how REDEMPLO’s first European approval for a rare, severe triglyceride disorder could reshape Arrowhead’s broader investment narrative.

    We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

    Arrowhead Pharmaceuticals Investment Narrative Recap

    To own Arrowhead, you need to believe its RNAi platform can convert late stage assets into durable commercial products, while the company manages substantial ongoing losses. REDEMPLO’s European authorisation is an important validation of plozasiran in FCS, but it does not remove the short term risk that cash burn and rising R&D and SG&A outlays continue to outpace revenue, especially with much of current income still tied to milestones and collaborations.

    The most directly relevant recent announcement is Arrowhead’s Q3 2026 earnings, which showed US$75.25 million in sales but a wider net loss of US$194.28 million. This contrast highlights the execution test now facing REDEMPLO and the broader cardiometabolic portfolio: early commercial and milestone revenues need to meaningfully offset a growing cost base, at a time when the company remains unprofitable and is not forecast to reach profitability over the next three years.

    Yet alongside this clinical progress, investors should still be aware that rising expenses and deepening losses could...

    Read the full narrative on Arrowhead Pharmaceuticals (it's free!)

    Arrowhead Pharmaceuticals' narrative projects $704.7 million revenue and $133.3 million earnings by 2029. This implies 4.3% yearly revenue growth and a $434.2 million earnings increase from -$300.9 million today.

    Uncover how Arrowhead Pharmaceuticals' forecasts yield a $89.08 fair value, in line with its current price.

    Exploring Other Perspectives

    ARWR 1-Year Stock Price Chart
    ARWR 1-Year Stock Price Chart

    Some of the lowest ranked analysts were assuming revenue could fall about 15% a year and still only reach roughly US$379 million by 2029, which is far more pessimistic than narratives that focus on REDEMPLO and broader RNAi approvals as key growth drivers, and shows just how differently you and others might assess Arrowhead’s future after this latest news.

    Explore 3 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth just $89.08!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Ready To Venture Into Other Investment Styles?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.